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Abstract
Invasive pulmonary aspergillosis (IPA) is an opportunistic fungal infection in patients under-
going chemotherapy for hematological malignancy, hematopoietic stem cell transplant, or
other forms of immunosuppression. In this group, Aspergillus infections account for the
majority of deaths due to mold pathogens. Although early detection is associated with
improved outcomes, current diagnostic regimens lack sensitivity and specificity. Patients
undergoing chemotherapy, stem cell transplantation and lung transplantation were enrolled
in a multi-site prospective observational trial. Proven and probable IPA cases and matched
controls were subjected to discovery proteomics analyses using a biofluid analysis platform,
fractionating plasma into reproducible protein and peptide pools. From 556 spots identified
by 2D gel electrophoresis, 66 differentially expressed post-translationally modified plasma
proteins were identified in the leukemic subgroup only. This protein group was rich in com-
plement components, acute-phase reactants and coagulation factors. Low molecular
weight peptides corresponding to abundant plasma proteins were identified. A candidate
marker panel of host response (9 plasma proteins, 4 peptides), fungal polysaccharides
(galactomannan), and cell wall components (β-D glucan) were selected by statistical filter-
ing for patients with leukemia as a primary underlying diagnosis. Quantitative measure-
ments were developed to qualify the differential expression of the candidate host response
PLOSONE | DOI:10.1371/journal.pone.0143165 November 18, 2015 1 / 21
a11111
OPEN ACCESS
Citation: Brasier AR, Zhao Y, Spratt HM, Wiktorowicz
JE, Ju H, Wheat LJ, et al. (2015) Improved Detection
of Invasive Pulmonary Aspergillosis Arising during
Leukemia Treatment Using a Panel of Host
Response Proteins and Fungal Antigens. PLoS ONE
10(11): e0143165. doi:10.1371/journal.pone.0143165
Editor: Ilse D. Jacobsen, Leibniz Institute for Natural
Products Research and Infection Biology- Hans
Knoell Institute, GERMANY
Received: June 18, 2015
Accepted: November 2, 2015
Published: November 18, 2015
Copyright: © 2015 Brasier et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by the following
grants: the NIAID Clinical Proteomics Center,
HHSN272200800048C (ARB), UL1TR000071 UTMB
CTSA (ARB), NIEHS P30 ES006676 (ARB), and the
Aspergillus Technology Consortium NIAID Contract #
HHSN266200700023C (JW). The funding agencies
had no role in study design, data collection, analysis,
decision to publish or preparation of the manuscript.
proteins using selective reaction monitoring mass spectrometry assays, and then applied to
a separate cohort of 57 patients with leukemia. In this verification cohort, a machine learning
ensemble-based algorithm, generalized pathseeker (GPS) produced a greater case classi-
fication accuracy than galactomannan (GM) or host proteins alone. In conclusion, Integra-
tion of host response proteins with GM improves the diagnostic detection of probable IPA in
patients undergoing treatment for hematologic malignancy. Upon further validation, early
detection of probable IPA in leukemia treatment will provide opportunities for earlier inter-
ventions and interventional clinical trials.
Introduction
Aspergillus is an important opportunistic fungal pathogen affecting immunocompromised
patients, and the disease is associated with high mortality [1, 2]. Invasive aspergillosis is the
most common type of fungal infection among stem cell transplant recipients and is the second-
most common type of fungal infection among solid organ transplant recipients, with a
12-month cumulative incidence of 19% [3]. Despite intense surveillance and institution of
early aggressive anti-fungal therapy, case fatality rates are as high as 50 to 90% depending on
underlying disease and site of infection [4, 5].
Aspergillus spp are ubiquitous environmental molds whose conidia are easily aerosolized
[6]. In the presence of normal innate and adaptive immune systems, airborne fungal spores are
usually cleared by resident macrophages that phagocytose and destroy them [7]. In patients
with an intact immune response, Aspergillus is responsible for a spectrum of diseases ranging
from aspergilloma, allergic sinusitis or bronchopulmonary aspergillosis, to chronic necrotizing
pulmonary aspergillosis. By contrast, in patients with suppressed immunity such as those
undergoing hematopoietic stem cell transplant, organ transplant, or those undergoing induc-
tion therapy for hematological malignancy, Aspergillus can cause aggressive and invasive infec-
tion leading to devastating outcome [6]. Specifically, in patients with acute leukemia,
prolonged periods of neutropenia and dysfunctional macrophages are major risk factors for
invasive pulmonary aspergillosis [IPA; ref [8]].
Within the immunocompromised airway, colonizing conidia germinate into a replicative
and invasive hyphal form, producing angioinvasion, inflammation, and hematogenous fungal
spread. In the invasive stages, the fungus disseminates via the blood to involve multiple organ
systems including the liver and central nervous system [6]. Because of its protean manifesta-
tions, IPA is difficult to diagnose early in the course of infection. Clinically, diagnosis of IPA is
established on the basis of radiographic, culture, and fungal antigen detection in high-risk
patients [6, 9]. Despite hematogenous dissemination, fungal blood cultures are rarely positive
[10]. The development of fungal antigen assays has added to the available diagnostic tools.
Here, clinical grade ELISA assays for galactomannan (GM), a polysaccharide produced during
hyphal growth [11], and (1, 3)-β-D-glucan (BG), a fungal cell wall component, have been
developed [12]. Although GM and BG measurement in blood are used clinically for the detec-
tion of opportunistic fungal diseases, these tests are subject to false positive and false negative
effects, thereby limiting their clinical usefulness [11, 13]. More sensitive and accurate diagnos-
tic panels will have impact on the management and morbidity from IPA.
Because prompt diagnosis of IPA improves survival [14, 15], we sought to discover, qualify,
and verify a panel of protein biomarkers associated with proven and probable IPA using plasma
specimens from the Aspergillosis Technology Consortium (AsTeC) and proteomics analysis
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performed by the UTMB Clinical Proteomics Center (CPC). We hypothesized that the inclusion
of host response proteins to that of fungal antigens would improve the early detection of IPA.
Materials and Methods
Ethical approval
This study was conducted by the Aspergillus Technology Consortium (AsTeC) under approval
by the University of Florida Institutional Review Board (IRB) protocol 073–2008 and by the
UTMB Clinical Proteomics Center (CPC) under approval from UTMB IRB No. 08–258. This
study was compliant with all applicable federal regulations governing the protection of human
subjects. Most subjects were adults who provided written, informed consent prior to participa-
tion in the study. Subjects under the age of 18 provided either written informed consent or
assent with parent/guardian providing written consent.
Study design
Three patient populations at high risk for IPA were enrolled by informed consent or assent at
the start of their transplant or chemotherapy treatment at the 3 AsTeC collection sites. These
included subjects undergoing hematopoietic stem cell transplant, subjects receiving intensive
chemotherapy for hematologic malignancies, and subjects receiving lung transplants. Each
patient was scored for IPA status (proven, probable or no IPA) using case definitions estab-
lished by the Mycoses Study Group / European Organization for Research and Treatment of
Cancer (MSG/EORTC) [16, 17].
All cases included in this study met the 2008 revised EORTC/MSG criteria of proven or
probable IPA ([16]; diagnostic criteria are shown in S1 Table). Of the 61 IPA cases, serum GM
was assayed in 60- of which 36 tests were positive (S2 Table). Bronchoalveolar lavage GM was
assayed in 35 cases- of which 30 were positive. A positive serum GM was the only mycological
criteria in 22 of the 61 cases. Independent testing of GM was performed on all IPA cases using
serum collected on the same day as samples used for proteomics analysis. Those who developed
probable or proven IPA where selected for subsequent proteomics studies. The median time
between IPA case sample collection and EORTC date was 0 days (range 67 days before EORTC
to 38 days after EORTC).
Blood samples were also available from 17 cases prior to their diagnosis of probable IPA,
termed “auto-controls”. The median days between auto control sample collection and EORTC
date was 28 days before EORTC (range 10–390 days). Cases with other concomitant fungal
infections were excluded. No invasive fungal infections were identified in the control group.
Bacterial sepsis was present in 3 of the controls within 7 days before or after the sample used
for testing in this study. Controls without IPA were selected from the same cohort, and
matched for gender, age and recruiting center.
Because no host response proteins have yet been discovered clinically for the diagnosis of
IPA, we undertook a broad discovery approach for discriminant features in plasma using tar-
geted immunoassays, as well as discovery proteomics and analysis of discriminant peptides
using the biofluids analysis platform (BAP, schematically diagrammed in Fig 1).
Sample QA/QC and analysis
Blood was collected in a closed system Vacutainer1 CPT™ Cell Preparation Tube anti-coagu-
lated with sodium citrate (Becton, Dickinson and Company, Franklin Lakes, New Jersey). The
plasma fraction was separated from cells and frozen at -80°C using a standard operating proce-
dure implemented across all study sites. Blood was also collected in BD Vacutainer1 Plus
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plastic serum tubes (Becton, Dickinson and Company, Franklin Lakes, New Jersey, separated
by centrifugation and serum frozen at -80°C for GM and BG testing. All samples and clinical
data were de-identified and linked to an anonymous study ID number at the AsTeC Bioreposi-
tory. For proteomics assays, each plasma sample was assayed for protein content, and a few
randomly selected for cysteine content estimation by amino acid analysis (for quantitative cys-
teine-specific fluorescence-labeling). Plasma protein profiles were determined for all samples
by capillary electrophoresis. For the 2D gel electrophoresis (2DE) and peptide analyses, speci-
mens were randomized for proteomics analysis.
Biofluid Analysis Platform (BAP) Fractionation and 2DE
The BAP pre-separation fractionation system is a semi-automated device that fractionates
denatured plasma into protein and peptide pools as described earlier in detail [18]. The protein
Fig 1. Schematic view of panel development for pulmonary IPA. Schematic view of strategy for discovery, qualification, and verification of panel-based
classifiers. The BAP fractionation platform fractionates proteins and peptides for analysis by automated size exclusion chromatography (SEC). Candidate
biomarkers were assembled based on proteins identified in the discovery phase and by previous studies. For each candidate, targeted proteomics assays
using stable isotope dilution (SID)-selected reaction monitoring (SRM) assays were developed, standardized, and used to quantitate the abundance of the
candidate biomarker in the discovery population (qualification). Nonparametric statistical filters were used to identify 15 host response proteins/peptides and
2 fungal polysaccharides. SID-SRM-MSmeasurement of host-response proteins and peptides were used to test RF classifier performance.
doi:10.1371/journal.pone.0143165.g001
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pools were depleted of the 14 most highly abundant proteins and labeled with BODIPY FL-
maleimide (BD) [19, 20]. BD-labeled proteins were separated by 2DE, imaged, and analyzed
using SameSpots software (Totallab, Ltd. Newcastle Upon Tyne, UK). The peptide pools were
digested and stable isotope labeled using trypsin digestion in the presence of H2
18O, described
in detail below.
Protein Identification
2DE spots that were significantly differentially expressed were picked robotically, trypsin-
digested, and peptides identified by MALDI TOF/TOF (AB Sciex 5800, Foster City, CA). Data
were analyzed with the AB Sciex software package included with the instrument: TOF/TOF
Series Explorer (v. 4.1.0) with Oracle Database Schema (v. 4.0.0), and Data Version (v. 4.0.5) to
acquire both MS and MS/MS spectral data, respectively. The instrument was operated in posi-
tive ion reflectron mode, mass range was 850–3000 Da, and the focus mass was set at 1700 Da.
For MS data, 600–1000 laser shots were acquired and averaged from each sample spot. Auto-
matic external calibration was performed using a peptide mixture with reference masses
904.468, 1296.685, 1570.677, and 2465.199.
Following MALDI MS analysis, MALDI MS/MS was performed on several (5–10) abundant
ions from each sample spot. A 1kV positive ion MS/MS method was used to acquire data
under post-source decay (PSD) conditions. The instrument precursor selection window was
+/- 3 Da. For MS/MS data, 1500 laser shots were acquired and averaged from each sample
spot. Automatic external calibration was performed using reference fragment masses 175.120,
480.257, 684.347, 1056.475, and 1441.635 (from precursor mass 1570.700).
AB Sciex ProteinPilot software was used in conjunction with MASCOT to search the respec-
tive protein database using both MS andMS/MS spectral data for protein identification. Protein
match probabilities were determined using expectation values and/or MASCOT protein scores.
MS peak filtering included the following parameters: mass range 850 Da to 3000 Da, minimum
S/N filter = 10, mass exclusion list tolerance = 0.5 Da, and mass exclusion list (for some trypsin
and keratin-containing compounds) included masses 842.51, 870.45, 1045.56, 1179.60, 1277.71,
1475.79, and 2211.1. For MS/MS peak filtering, the minimum S/N filter = 10. For protein identi-
fication, theHomo sapiens taxonomy was searched in the NCBI database. Other parameters
included the following: trypsin proteolysis; 1 maximummissed cleavage; fixed modifications
included carbamidomethyl (C) for 2DE analyses only; variable modifications included oxidation
(M); precursor tolerance was set at 0.5 Da; MS/MS fragment tolerance was set at 0.5 Da;
mass = monoisotopic; and peptide charges were only considered as +1. The entire protein list
was also searched for the Aspergillus database (http://www.aspergillusgenome.org). Species
searched included Aspergillus clavatusNRRL 1; Aspergillus flavusNRRL 3357; Aspergillus fumi-
gatus A1163, Af293; Aspergillus nidulans FGSC A4; Aspergillus niger ATCC 1015, CBS 513.88;
Aspergillus oryzae RIB40/ATCC 42149; Aspergillus terreusNIH2624 andNeosartorya fischeri
NRRL 181.
Peptide analysis
The peptide pools obtained from the BAP were differentially labeled with 16/18O by trypsin-
mediated exchange. To ensure maximum incorporation of two oxygen isotopes at each car-
boxy-terminus, the catalytic incorporation of the first oxygen is performed at pH 8.0 and the
second non-catalytic exchange is performed at pH 6.0 for 24 h. Incorporation is monitored by
triple quadrupole mass spectrometry. Labeled peptides were then separated by RP-HPLC, and
quantified and identified by a tandem electrospray MS/MS (AB 4000 Q-trap). 18 peptides were
detected in greater than 50% of the sample set. These were developed into independent
Classification of IPA Using Host Response Proteins
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SID-SRM assays for exact measurement and assessment for differential expression. Of these, 3
were statistically significant between cases and controls.
Multiplex ELISA
Plasma concentrations of interleukin (IL)-6, -10, tumor necrosis factor (TNF)-α, plasminogen
activator inhibitor (PAI)-1, Factor VIII, and VonWillebrands’s factor (vWF) were assayed by
sandwich ELISA (Bioplex, Bio-Rad, Hercules, CA) as previously described [18]. Data were log2
normalized for stastistical analysis and modeling.
Stable Isotope Dilution (SID)-Selected Reaction Monitoring (SRM)-MS
Signature peptides with their native flanking sequences around the trypsin cleavage site were
chemically synthesized incorporating isotopically labeled [13C6
15N4] arginine or [
13C6
15N2]
lysine to a 99% isotopic enrichment (Thermo Scientific). For intact protein analysis, 5 μL of
plasma samples were denatured with 145 μL of 8M urea. Known amounts of stable isotope
labeled peptide standards were spiked into each sample. After reduction/alkylation with DTT
and iodoacetamide, the plasma samples were digested with trypsin. The peptides were desalted
with C18-ZipTip (Millipore, MA) prior to LC-MS analysis. For plasma peptides collection, 3
mg of plasma protein, 8 M urea, and 3 μg of purified Alexa-488 labeled thaumatin (Sigma-
Aldrich, St. Louis, MO) in a final volume of 300 μL, were fractionated into “peptide pools” by
SEC in BAP. Known amount of stable isotope labeled standard peptides were added into the
peptide pool and digested with trypsin. The tryptic peptides were desalted with SepPak C18
cartridge (Waters, MA), and subjected to SID-SRM.
LC-SRM-MS analysis was performed with a TSQ Vantage triple quadrupole mass spectrom-
eter equipped with nanospray source (Thermo Scientific, San Jose, CA). The online chroma-
tography were performed using an Eksigent NanoLC-2D HPLC system (AB SCIEX, Dublin,
CA). An aliquot of 10 μL of each of tryptic digests were injected on a C18 reverse-phase nano-
HPLC column (PicoFrit™, 75 μm x 10 cm; tip ID 15 μm) at a flow rate of 500 nL/min with a
20-min 98% A, followed by a 15-min linear gradient from 2–30% mobile phase B (0.1% formic
acid-90% acetonitrile) in mobile phase A (0.1% formic acid). The TSQ Vantage was operated
in high-resolution SRMmode with Q1 and Q3 set to 0.4 and 0.7-Da Full Width Half Maxi-
mum (FWHM). All acquisition methods used the following parameters: 2100 V ion spray volt-
age, a 275°C ion transferring tube temperature, a collision-activated dissociation pressure at 1.5
mTorr, and the S-lens voltage used the values in S-lens table generated during MS calibration.
All SRM data were manually inspected to ensure peak detection and accurate integration.
The chromatographic retention time and the relative product ion intensities of the analyte pep-
tides were compared to those of the stable isotope labeled standard (SIS) peptides. The varia-
tion of the retention time between the analyte peptides and their SIS counterparts should be
within 0.05 min, and the difference in the relative product ion intensities of the analyte peptides
and SIS peptides were below 20%. The peak area in the extract ion chromatography of the
native and SIS version of each signature peptide were integrated using Xcalibur1 2.1. The
default values for noise percentage and base-line subtraction window were used. The ratio
between the peak area of native and SIS version of each peptide were calculated. Two technical
replicates of analysis for each sample were performed and each technical replicate was analyzed
by SRM-MS twice. Within-technical replicates were used to assess assay reproducibility.
Galactomannan (GM) assay
The Platelia Aspergillus enzyme immunoassay (EIA) (Bio-Rad Laboratories, Redmond, WA)
was performed according to the manufacturer’s procedures at MiraVista Laboratories
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(Indianapolis, IN, Ref [13]). Results were expressed as GM indices defined as the ratio of the
optical density (OD) value of the sample to the OD value of a standard sample containing 1 ng
of GM.
Independent testing of GM was performed on all IPA cases using serum collected on the
same day as samples used for proteomics analysis. The median number of days between clinical
diagnostic serum GM and independent testing was 3.5 days (range 41 days before clinical diag-
nostic to 57 days after clinical diagnostic). GM and independently tested serum GM were the
same (positive or negative) in 44 of the 60 cases tested (S2 Table). Of the 14 cases where clinical
GM and study GM differed, all clinical diagnostic GM tests were positive and independently
tested GM were negative. In addition, of these 14 cases, 13 were undergoing antifungal therapy
at the time of collection of the independent tested GM sample, and in 1 case, the sample was
collected 4 days after antifungal therapy concluded. Only serum was used for GM analysis. The
cut off for determination of positive GM was GM 0.5.
(1, 3)-beta-D-glucan (BG) assay
BG testing was performed at MiraVista Diagnostics (Indianapolis, IN) using the Fungitell
assay (Associates of Cape Cod Inc., East Falmouth, MA), in accordance with the manufac-
turer's instructions [21]. For the purposes of our study, specimens were tested in duplicate and
BG levels were reported numerically (12).
Statistical analysis and model
Statistical comparisons were performed using SPSSv20 (SPSS, Inc., Chicago, IL). 2-way
ANOVA, Mann-Whitney, chi-squared and Kruskall Wallis tests were applied as indicated. One
way ANOVA was performed on the log2 transformed spot volumes. The significance level in all
instances was 0.05. Random Forests [22, 23], CART, and multivariate regression spline (MARS)
modeling was performed by 10-fold cross validation using Salford Predictive Modeler (v7.0, Sal-
ford Systems Inc). Data were z-scored prior to model building. Measurements from the discov-
ery cohort were used as the “training” data set, and those from the verification cohort as the
“test” data set. Model performance was evaluated by analysis of the AUC of the ROC curve,
where sensitivity (true positive) vs 1-specificity (false positive) was plotted and assessment of
classification accuracy [22]. Modeling in Random Forests assigned weights to outcomes with
case = 1 and control = 0.5 in order to obtain better performance in predicting cases.
Results
The participants in the discovery cohort were composed of 46 unique men and 22 unique
women, with a mean age of 52.66 ± 13.59 years. Forty six patients had leukemia as an underly-
ing disease with 22 other (lung- and hematopoietic stem cell transplants). In 17 cases, blood
samples were available from the surveillance study that were taken prior to the diagnosis of
probable IPA; these samples termed “auto” controls were also included in the discovery analy-
sis to minimize th effects of individual variations in the plasma proteome on the biomarker
identification. There was no statistical difference in the ages, gender distribution, primary diag-
nosis, center collection site or neutrophil count between the case and control groups (Table 1).
Patients with hematological malignancies underwent intensive chemotherapy producing pro-
longed neutropenia. The distribution of treatment type for cases and controls is shown in
Table 2.
Because previous studies demonstrated increased circulating levels of cytokines endothelial-
derived proteins in patients with chronic necrotizing pulmonary aspergillosis [24]., we mea-
sured IL-6 and -10, tumor necrosis factor (TNF)- α, PAI-1, Factor VIII, and vWF. Of these
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measurements, only IL-6 was significantly elevated in case over that of control (p<0.05, Wil-
coxon Ranked Sum Test, S3 Table and S1 Fig).
We next applied discovery proteomics to identify differentially abundant proteins using an
unbiased protein profiling strategy (BAP; Methods and Fig 1). Five hundred fifty-six spots
were detected by 2DE; of these, 66 were identified to be statistically significant across the
groups (Table 3). High confidence identifications of anti-proteases, acute-phase inducible
products of the complement and coagulation cascades, and apolipoproteins were found. Inter-
estingly, multiple identifications of the same protein were observed as both different isoelectric
forms and apparent molecular weight. For example, fibrinogen beta (FIBB) was observed at
isoelectric points (pIs) of 7.66 and 5.99 (spots 1, 2 in Table 3) and hemopexin (HPX) was
observed at pIs of 5.02 and 6.35 (spots 17, 18 in Table 3). FIBA was observed at two distinct
Table 1. Characteristics of study cohorts.
Cohort Disease Age, years
(mean ± S.D.)
GenderNo.
(M/F)
Underlying Disease,
number (Leukemia/Other)
Absolute Neutrophil Count
(billion cells/L) (Median (IQR))
Discovery
(N = 85)
ControlN = 34 48.35 ± 14.79 yr 20/14 25/9 1.3 (0.3, 3.9)
AutoN = 17 54.17 ± 11.27 yr 10/7 9/8 1.3 (0.4, 3)
CaseN = 34 56.97 ± 10.87 yr 20/14 21/13 0.3 (0, 1.8)
Total SamplesN = 85 52.96 ± 13.10 yr 50/35 55/30 1.0 (0.1, 3.1)
Total Unique
IndividualsN = 68
52.66 ± 13.59 yr 40/28 46/22 0.9 (0.1, 3.0)
Qualiﬁcation
(N = 37)
ControlN = 20 49.2 ± 16.68 yr 13/7 20/0 2.5 (0.7, 5.3)
CaseN = 17 57.12 ± 12.18 yr 10/7 17/0 0.0 (0.0, 0.8)
TotalN = 37 52.84 ± 15.12 yr 23/14 37/0 1.1 (0.0, 3.1)
Veriﬁcation
(N = 57)
ControlN = 30 50.27 ± 15.17 yr 23/7 30/0 1.5 (0.1, 3.7)
CaseN = 27 55.07 ± 13.31 yr 20/7 27/0 0.1 (0.0, 1.7)
TotalN = 57 52.54 ± 14.4 yr 43/14 57/0 0.4 (0.0, 3.0)
doi:10.1371/journal.pone.0143165.t001
Table 2. Treatment regimens for case and controls, by diagnosis.
TREATMENT CATEGORY IPA CASES MATCHED CONTROLS
BMT 22 29
Allo 21 29
Auto 1 0
Hem. Malig. 37 34
AML 24 28
CLL 5 1
MDS 3 1
NHL 2 1
ALL 1 2
CML 1 1
CMML 1 0
Lung Transplant (COPD) 1 1
doi:10.1371/journal.pone.0143165.t002
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Table 3. Protein Identification.
NO. PROTEIN NAME ACC
NO
PI MW MS EXPEC.
VALUE
P-VALUE ABUNDANCE RATIO (CASE VS
CONTROL)
1 Fibrinogen beta chain P02675 7.66 51 1.26E-16 0.030148 1.16
2 Fibrinogen beta chain P02675 5.99 49 3.97E-14 0.049690 1.14
3 Alpha-mannosidase 2 Q16706 7.51 36 1.99E+01 0.003111 -1.41
4 Ig kappa chain V-III region P01620 8.19 35 9.98E-12 0.000343* -1.54
5 Ig kappa chain V-III region P01620 7.15 35 1.58E-04 0.000673* -1.82
6 Ferritin light chain P02792 7.04 31 3.97E-13 0.000492* 2.12
7 Leucine-rich alpha-2-glycoprotein P02750 8.12 17 1.58E-24 0.001784 1.71
8 Complement factor B P00751 7.31 73 7.92E-09 0.037614 -1.31
9 Hemopexin HPX P02790 7.38 31 6.29E-03 0.005740 -1.36
10 Serum amyloid A-4 protein P35542 3.76 25 5.00E-01 0.001691 -1.44
11 Fibrinogen alpha chain P02671 5.37 19 6.29E-37 0.031877 1.25
12 Leucine-rich alpha-2-glycoprotein P02750 8.21 17 1.26E-26 0.002389 1.43
13 Fibrinogen alpha chain P02671 3.96 12 1.99E-14 0.005660 -1.37
14 Complement C3 P01024 5.60 48 1.58E-30 0.005304 -1.31
15 Complement C4-A P0C0L4 7.25 42 1.99E+00 0.013122 -1.35
16 Histidine protein methyltransferase 1 homolog
METTL18
O95568 7.55 31 3.97E+01 0.043937 -2.32
17 Hemopexin HPX P02790 5.22 30 2.51E-04 0.010053 -1.28
18 Hemopexin HPX P02790 6.35 30 1.58E+01 0.037373 -1.28
19 Keratin, type II cytoskeletal 1 P04264 9.26 29 3.15E-03 0.043690 -1.12
20 Serum amyloid A-4 protein P35542 6.68 26 1.58E-05 0.047502 -1.31
21 MEF2-activating motif and SAP domain-containing
transcriptional regulator
Q6ZN01 8.10 20 2.51E+01 0.046841 -1.58
22 Apolipoprotein A-II P02652 7.03 20 6.29E-05 0.021182 -1.36
23 Alpha-1-antichymotrypsin P01011 5.00 19 1.99E-60 0.005314 1.38
24 Alpha-1-antichymotrypsin P01011 7.74 19 9.98E-60 0.020735 1.33
25 Alpha-1-antichymotrypsin P01011 5.51 19 3.15E-19 0.004400 1.60
26 Alpha-1-antitrypsin P01009 4.87 17 9.98E-01 0.003011 1.33
27 Leucine-rich alpha-2-glycoprotein P02750 6.33 17 6.29E-34 0.008686 1.29
28 Leucine-rich alpha-2-glycoprotein P02750 9.18 17 2.51E-36 0.009977 1.37
29 Alpha-1-antitrypsin P01009 3.85 16 1.26E-12 0.031016 1.29
30 Alpha-1-antitrypsin P01009 4.81 16 1.26E-23 0.042439 1.37
31 Alpha-1-acid glycoprotein 1 P02763 5.05 14 1.58E-05 0.001129 1.54
32 Alpha-1-acid glycoprotein 1 P02763 7.82 14 1.58E-01 0.003841 1.51
33 Apolipoprotein A-I P02647 8.83 13 2.51E-20 0.024695 -1.35
34 Apolipoprotein A-I P02647 7.59 13 3.97E-06 0.006216 -1.44
35 Apolipoprotein A-I P02647 6.74 12 3.15E-33 0.021568 -1.33
36 Alpha-1-acid glycoprotein 1 P02763 4.81 12 9.98E-08 0.001122 1.51
37 Serum albumin P02768 6.70 35 3.97E-06 0.022091 1.26
38 Alpha-1-antichymotrypsin P01011 5.60 19 3.97E-55 0.036387 1.35
39 Alpha-1-antichymotrypsin P01011 5.75 19 1.58E-48 0.041962 1.42
40 Alpha-1-antichymotrypsin P01011 6.14 19 1.26E-48 0.006482 1.43
41 Alpha-1-antichymotrypsin P01011 5.25 19 9.98E-47 0.004255 1.50
42 Leucine-rich alpha-2-glycoprotein P02750 8.99 17 2.51E-32 0.002945 1.35
43 Leucine-rich alpha-2-glycoprotein P02750 9.09 17 3.97E-30 0.004495 1.33
44 Leucine-rich alpha-2-glycoprotein P02750 5.90 17 3.97E-34 0.004792 1.31
45 Alpha-1-antitrypsin P01009 3.52 16 9.98E-40 0.045945 1.33
(Continued)
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molecular weights of 19 kDa and 12 kDa (spots 11 and 13 in Table 3). These observations indi-
cate active enzymatic modification or proteolysis, respectively by IPA.
Genome ontology enrichment analysis showed significant overrepresentation of comple-
ment cascade (5-fold enrichment, p< 1.55 X 10−2). Consistent with the lack of circulating
organisms in patients with acute IPA [10], no high confidence protein matches were obtained
by searching peptide fingerprints within multiple Aspergillus databases (Materials and Meth-
ods). From these data we concluded that complement and coagulation cascades were compo-
nents of the host response to IPA, and that active post-translational modification of these
proteins were produced, perhaps through their consumption or proteolysis as a consequence
of angio-invasion. Quantitative SID-SRM-MS analyses were developed for candidate plasma
proteins (Fig 2, Table 4).
Based on the observation that proteolytic fragments of complement, acute-phase, and coag-
ulation factors were detected in IPA cases, and the knowledge that angio-invasion is locally tis-
sue destructive, we focused biomarker identification on the peptide pools. To accomplish this,
we designed quantitative SID-SRM-MS for the 18 peptides represented in>50% of samples.
Four peptides were significantly different; these assays are shown in Table 5.
Table 3. (Continued)
NO. PROTEIN NAME ACC
NO
PI MW MS EXPEC.
VALUE
P-VALUE ABUNDANCE RATIO (CASE VS
CONTROL)
46 Alpha-1-antitrypsin P01009 8.16 16 3.15E-33 0.000936 1.48
47 Alpha-1-acid glycoprotein 1 P02763 4.57 14 3.15E-23 0.014537 1.51
48 Alpha-1-acid glycoprotein 1 P02763 3.55 14 3.97E-19 0.005862 1.48
49 Alpha-1-acid glycoprotein 1 P02763 3.99 12 9.98E-21 0.002073 1.45
50 Alpha-1-acid glycoprotein 1 P02763 4.64 12 3.15E-19 0.021949 1.39
51 12345 Serum albumin P02768 9.47 109 6.29E-42 0.027907 -1.12
52 Serum albumin P02768 8.14 73 3.97E-17 0.000148* -1.62
53 Serum albumin P02768 8.20 73 6.29E-35 0.003984 -1.39
54 Complement C4-A P0C0L4 6.22 73 3.97E-12 0.035901 -1.56
55 Fibrinogen alpha chain P02671 6.22 12 1.99E-14 0.045355 -1.42
56 Fibrinogen beta chain P02675 5.52 51 9.98E-27 0.001817 1.29
57 Fibrinogen beta chain P02675 5.60 51 9.98E-37 0.007696 1.27
58 Putative uncharacterized protein C6orf50 C6orf50 Q9HD87 6.25 26 3.15E+01 0.001200 -1.76
59 Transthyretin P02766 6.95 26 1.99E+00 0.001374 -1.48
60 Transthyretin P02766 4.00 26 1.58E-19 0.000343* -1.50
61 Transthyretin P02766 5.35 26 2.51E-20 0.000116* -1.62
62 Apolipoprotein C-III P02656 5.36 20 3.15E-11 0.013668 -1.63
63 Zinc-alpha-2-glycoprotein P25311 7.65 17 1.99E-06 0.037615 1.25
64 Histidine protein methyltransferase 1 homolog
METTL18
O95568 5.56 12 1.99E+01 0.022806 -1.39
65 Annexin A10 Q9UJ72 6.84 15 2.51E+01 0.000098* -2.21
66 Transthyretin P02766 6.76 14 1.26E+00 0.000011* -1.97
Protein identiﬁcation was performed using a Bayesian algorithm where matches were characterized by an expectation score, which represents an
estimate of the number of matches that would be expected in that database if the matches were completely random. Signiﬁcance was determined by one-
way ANOVA using log2 transformed spot volumes.
*, signiﬁcantly different after Benjamini-Hochburg correction for multiple hypothesis testing.
These values are for spot 4, p = 0.038105; spot 5, p = 0.046795; spot 6, p = 0.039113; spot 52, p = 0.020548; spot 60, p = 0.031786; spot 61,
p = 0.021551; spot 65, p = 0.027383; and spot 66 p = 0.005949.
doi:10.1371/journal.pone.0143165.t003
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We subjected the discovery data to subgroup analysis. Although there was no difference by
gender, the 8 candidate plasma proteins, 4 peptides, BG, and GM were different in cases vs con-
trols of patients with primary underlying diagnosis of leukemia. None of these candidates were
different between cases vs controls for other primary diagnoses (e.g., hematopoietic stem cell-
or lung transplant). We therefore focused on development of a biomarker panel only for
patients with the primary underlying diagnosis of leukemia.
Assembly and qualification of a candidate biomarker panel for IPA in
patients with primary diagnosis of leukemia
We then developed highly selective SID-SRM-MS assays for the most informative 8 candidate
proteins and 4 peptides and independently measured these in the leukemic qualification cohort
(Table 1) to confirm their differential expression. Assay characteristics are shown in Tables 4
Fig 2. Reference gel of plasma proteins dysregulated by IPA. Shown is a reference gel of 2DE of SEC fractionated and IgY depleted plasma proteins
from the study subjects. The location of 9 spots, identified as candidate discriminant proteins are shown. Spot #1 is FIBB; #2 is ALBU; #3 is AATL; #4 is
A1AT; #5 is LRG1; #6 is A1AG1; #7 is APO A1; #8 is FIBA; and #9 is APO C3. The image shown represents the pI range of 3–10 and the molecular size
range of 25–200+ kDa. Inset, average abundance of each protein spot is shown graphically for Case (Left) and Control (Right) as shown for protein spot # 1.
doi:10.1371/journal.pone.0143165.g002
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and 5. These results showed that the measurement of fungal antigens by ELISA and those of
the host response proteins and peptides by SID-SRM-MS were significantly different between
cases and controls (Fig 3A). Although GM and BG were significantly elevated in cases vs con-
trols, the distribution of values was highly skewed with many probable IPA cases having low
Table 4. SID-SRM-MS assays for candidate plasma proteins.
Protein Name Accession
#
Gene
Name
Sequence Q1 m/z Q3 m/z CE
(V)
Pre
Z
Prod
Z
Ion
type
Serum albumin P02768 ALBU LVNEVTEFAK 575.3111 694.3765 23 2 1 y6
575.3111 823.4191 23 2 1 y7
575.3111 937.462 23 2 1 y8
575.3111 1036.53 23 2 1 y9
Apolipo-protein A-I P02647 APOA1 DYVSQFEGSALGK 700.8382 808.4194 27 2 1 y8
700.8382 936.478 27 2 1 y9
700.8382 1023.51 27 2 1 y10
700.8382 1122.578 26 2 1 y11
Alpha-1-antichymotrypsin P01011 AATC EIGELYLPK 531.2975 633.3965 21 2 1 y5
531.2975 819.4605 21 2 1 y7
531.2975 762.4391 21 2 1 y6
531.2975 932.5446 21 2 1 y8
Leucine-rich alpha-
2-glycoprotein
P02750 LRG1 GQTLLAVAK 450.7792 501.339 19 2 1 y5
450.7792 614.423 19 2 1 y6
450.7792 715.4707 19 2 1 y7
450.7792 843.5293 19 2 1 y8
Alpha-1-antitrypsin P01009 A1AT SVLGQLGITK 508.3109 659.4081 21 2 1 y6
508.3109 716.4296 21 2 1 y7
508.3109 829.5136 21 2 1 y8
508.3109 928.582 21 2 1 y9
Apolipo-protein C-III P02656 APOC3 DALSSVQESQVAQQAR 858.929 887.469 33 2 1 y8
858.929 1016.511 33 2 1 y9
858.929 1144.57 33 2 1 y10
858.929 1243.638 33 2 1 y11
Fibrinogen beta chain P02675 FIBB SILENLR 422.748 531.288 18 2 1 y4
422.748 644.372 18 2 1 y5
422.748 757.456 18 2 1 y6
422.748 844.488 18 2 1 y7
Alpha-1-acid glycoprotein 1 P02763 A1AG1 YVGGQEHFAHLLILR 876.9808 982.6191 33 2 1 y8
876.9808 1119.678 32 2 1 y9
876.9808 1248.721 31 2 1 y10
876.9808 835.5507 33 2 1 y7
Fibrinogen alpha chain P02671 FIBA GLIDEVNQDFTNR 760.871 780.363 29 2 1 y6
760.871 894.406 29 2 1 y7
760.871 993.474 29 2 1 y8
760.871 1122.517 29 2 1 y9
760.871 1237.544 29 2 1 y10
For each of the candidate plasma proteins, SID-SRM-MS assays were developed. Shown is the protein accession number, common name, signature
sequence, quadrupole (Q) mass, optimized collision enegery (CE) and ion type measured. Pre, precursor. Prod, product.
doi:10.1371/journal.pone.0143165.t004
Classification of IPA Using Host Response Proteins
PLOS ONE | DOI:10.1371/journal.pone.0143165 November 18, 2015 12 / 21
values that overlapped with controls. We also observed that circulating alpha-1-acid glycopro-
tein (A1AG1), leucine rich globulin (LRG1), fibrinogen (FIB) -A and -B chains, and alpha anti-
trypsin (AATC)/ SERPINA1 proteins were elevated in IPA vs matched controls (Fig 3A). By
contrast, albumin (ALBU) and apolipoprotein (APO) A1 were reduced in IPA compared to
matched controls, as were retinol binding protein (RBP) and APOA2 peptides (Fig 3A). These
findings qualitatively reproduced our discovery results, indicating that IPA in leukemia is asso-
ciated with dysregulation of circulating anti-proteases and coagulation factors. However,
because the range of each protein measurement significantly overlapped that of the control
population, none of these markers was diagnostic in isolation. We therefore focused on devel-
oping a discriminant biomarker panel for patients with a primary underlying diagnosis of
leukemia.
Verification and predictive modeling for IPA
An independent group of 57 patients (43 males, 14 females) with an average age of 52.54 ± 14.4
years with a primary diagnosis of leukemia was tested as the verification cohort: Cases and con-
trols were indistinguishable for age, gender distribution, and neutrophil count (Table 1). More-
over the age and gender distribution of this verification cohort was not statistically different
than that of the original discovery cohort. We measured abundance of the candidate marker
panel consisting of 8 plasma proteins, 4 peptides and fungal antigens (Fig 3B). Although IL-6
was also observed to be increased in IPA, this marker contributed no independent information
and was not further pursued. In this verification cohort, the expression of fungal antigen (GM
and BG), host proteins (LRG1, FIBA and AATC), and 3 host peptides from APOA2 were con-
sistently significantly different between cases and controls, in the same relative expression pat-
tern as that observed in the discovery data analysis (cf. Fig 3A and 3B). We also noted that
although the differences in A1AG1, ALBU, APOA1, FIBB and A1AT did not achieve statistical
significance, the median values showed a similar directional trend as that seen in the discovery
cohort. These data constituted the independent verification data set for constructing discrimi-
nant classifiers.
Table 5. SID-SRM-MS assays for BAP peptides.
Protein Name Access # Gene Name_PreZ Sequence Q1 m/z Q3 m/z CE (V) Pre Z Prod Z Ion type
Retinol binding protein 4 Q5VY30 RBP4_599 YWGVASFLQK 599.8163 622.3553 24 2 1 y5
599.8163 693.3925 24 2 1 y6
599.8163 792.4609 24 2 1 y7
Apolipoprotein A-II P02652 APOA2_600 VKSPELQAEAK 600.3351 659.3717 24 2 1 y6
600.3351 788.4143 24 2 1 y7
600.3351 885.4671 24 2 1 y8
600.3351 972.4991 24 2 1 y9
Apolipoprotein A-II P02652 APOA2_486 SPELQAEAK 486.7534 546.2877 20 2 1 y5
486.7534 659.3717 20 2 1 y6
486.7534 788.4143 20 2 1 y7
Apolipoprotein A-II P02652 APOA2_578 SKEQLTPLIK 578.8504 684.4649 23 2 1 y6
578.8504 812.5234 23 2 1 y7
578.8504 941.566 23 2 1 y8
For each of candidate peptide puriﬁed by SEC in BAP, SID-SRM-MS assays were developed. Shown is the protein accession number, common name,
signature sequence, quadrupole (Q) mass, optimized collision enegery (CE) and ion type measured.
doi:10.1371/journal.pone.0143165.t005
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To identify the best method for combining the differentially expressed proteins, we evalu-
ated a group of machine learning classifiers for performance in the IPA discovery/qualification
data set using 10-fold cross validation. Recognizing that the data were not parametrically dis-
tributed, and the performance of machine learning classifiers are highly dependent on the
underlying data structures [22, 25], we evaluated the performance of classification and regres-
sion trees (CART), random forests (RF), multivariate regression spine (MARS), and general-
ized pathseeker (GPS) machine learning techniques by their classification accuracy and area
under the ROC curve (AUC). Although all classifiers evaluated generated accurate models on
the training data set, there were significant differences in their performance on the verification
data set (Table 6). Here, the GPS classifier produced the highest overall AUC (0.775) and the
smallest decrement in AUC between the qualification (training) and the verification (test) data
Fig 3. SID-SRM-MSmeasurements of candidate biomarkers in IPA. A). SID-SRM-MSmeasurements of the discovery cohort. For each candidate
biomarker, the SID-SRM-MSmeasurements by disease category are shown. Box plots show the 25% and 75% interquartile range and the median value,
indicated by horizontal dark line. Outliers are signified with circles. Note that the median horizontal line is not symmetrically located within the box plot,
signaling that the data are not normally distributed. P values are fromWilcoxon ranked sum. B). SID-SRM-MS of the validation cohort. Data are presented as
in Panel A.
doi:10.1371/journal.pone.0143165.g003
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set (Δ = 0.131). These data indicated that the GPS is the most robust classification approach for
the IPA data set.
Classification of IPA using fungal antigens
To evaluate the classification performance of fungal antigen measurement, we developed GPS-
based discriminant classifiers using GM as a continuous variable from the qualification cohort
as the training data set and those from the independent verification cohort as the test data set.
The GPS classifier using GM alone produced poor accuracy of 0.5 for both the training and test
data (Table 7). These data indicate that classifiers using fungal antigens alone are likely to be
unreliable.
Performance of the IPA RF classifier incorporating host response
proteins
We next constructed a discriminant classifier using the host response proteins and peptides
alone or combined with the fungal polysaccharides in the qualification cohort as the training
data set and performance evaluated on the verification data set, as above. Here, the GPS classi-
fier using combined fungal polysaccharides and host response proteins yielded the highest
accuracy on the verification data set than either the classifier using GM or host proteins alone
(Table 7).
The performance of the GPS classifier using host response proteins combined with fungal
polysaccharides for predicting IPA arising during chemotherapy treatment for leukemia was
assessed using several approaches. First, we examined the features most important for classifier
performance using the “variable importance” measure. Here, 10 host response proteins, the
top-most representing APOA1 p1, AATC and ALBU were the most informative features in the
classifier, each having variable importance values of>90% (Fig 4). Although BG and GM had
Table 6. Comparison of performance of machine learning classifiers.
PREDICTIVE MODEL Accuracy Accuracy Accuracy AUC AUC AUC
Train Test Δ Train Test Δ
CART 0.941 0.633 0.308 0.941 0.633 0.308
RF 0.821 0.594 0.227 0.891 0.69 0.201
MARS 0.916 0.632 0.284 0.959 0.689 0.27
GPS 0.740 0.557 0.183 0.906 0.775 0.131
Abbreviations: CART, classiﬁcation, and regression tree; RF, random forest; MARS, multivariate adaptive regression splines; GPS, generalized
pathseeker. For each classiﬁer, the area under the ROC curve (AUC), and Δ, the difference in AUC between the training and test data set are shown.
Note that the AUC of the RF classiﬁer is lowest, indicating that this classiﬁer will generalize to new data sets.
doi:10.1371/journal.pone.0143165.t006
Table 7. Comparison of variable performance of GPS classifiers.
Predictive Variables Accuracy Accuracy AUC AUC
Train Test Train Test
GM Only 0.50 0.50 0.699 0.863
Host Proteins Only 0.475 0.519 0.921 0.753
All 14 variables 0.74 0.557 0.906 0.775
For each classiﬁer, the area under the ROC curve (AUC), and Δ, the difference in AUC between the training and test data set are shown. Note that the Δ
AUC of the RF classiﬁer for all 14 variables is stable, indicating that this classiﬁer will generalize to new data sets. Accuracy represents case group only.
doi:10.1371/journal.pone.0143165.t007
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significant variable importances of 82% and 76%, respectively, these factors contributed less
information than the above-referenced host response proteins, (Fig 4). The performance of the
classifier using ROC is shown in Fig 5.
Discussion
Aspergillus is an opportunistic fungal pathogen that accounts for the greatest mortality due to
mold pathogen infections of immunocompromised patients, particularly those undergoing
chemotherapy for hematological malignancies [26]. In this setting, one of the most important
single risk factors is prolonged and profound neutropenia, indicating the primary role of the
neutrophil in preventing inhaled conidia from becoming invasive [8]. In neutropenia, early
diagnosis of IPA and prompt intervention with anti-fungal therapy improves survival [14, 15].
Despite this recognition and the availability of sensitive ELISAs for fungal cell wall components
and polysaccharides, the diagnosis of IPA is clinically imprecise [6, 9, 16]. In this study, we
sought to discover, qualify, and verify a panel of protein biomarkers associated with proven
and probable IPA. We applied discovery proteomics analyses in plasma samples obtained from
well-characterized patients participating in a prospective observational study. A candidate
marker panel consisting of 8 plasma host response proteins, 4 abundant protein fragments, a
fungal cell wall component (BG), and a fungal polysaccharide (GM) were selected by statistical
filtering. Our data suggest that addition of host response markers may be important additions
Fig 4. Candidate variable importance of the RF IPAmodel. Variable importance is a relative measurement from 0–100% that indicates the level that each
marker contributes to the performance of the classifier. Note the top three important variables are host response proteins.
doi:10.1371/journal.pone.0143165.g004
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to detect IPA, and will provide opportunities for earlier interventions and interventional clini-
cal trials.
In this study, we approached IPA biomarker discovery in plasma, because this represents an
clinically accessible biofluid in which aspergillosis antigens can be found [11]. However, the
discovery of biomarkers in plasma samples from humans is a challenging undertaking. Work
from the human plasma proteome project has shown that plasma contains high-abundance
proteins and tissue leak proteins that span a dynamic range of nearly 12 orders of magnitude
[27], including low-abundance proteins circulating in complexes with carriers [28]. Moreover,
pathological processes may induce the formation of post-translationally modified proteins and
proteolytic fragments that may be pathogenic for tissue-invasive disease, such as IPA. To
address these difficulties, we describe here the application of high recovery sample prefractio-
nation strategy to detect both proteins and peptides [18]. The initial denaturation of the plasma
prior to rapid SEC fractionation avoids the pitfall of peptide loss through its binding to high-
abundance plasma carrier proteins. Moreover, SEC is a nonadsorptive, high recovery prefrac-
tionation approach that achieves 95–100% recovery of the input protein. Finally, our develop-
ment of a quantitative saturation fluorescence labeling approach results in accurate,
quantitative 2DE to identify differentially expressed proteins [19, 29]. Here we observe that
alterations in isoelectric point and protein mass of abundant proteins important in the comple-
ment cascade occurs in a subset of patients with proven and probable IPA that would be other-
wise not detected using conventional “bottom-up” analysis of tryptic peptides. These changes
Fig 5. ROCCurve for the RF IPA prediction. ROC for GPS classifier using host response proteins, BAP peptides, and fungal antigens (BD and GM). AUC
values for training and test data sets are given in Table 6.
doi:10.1371/journal.pone.0143165.g005
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in isoelectric points suggest that these proteins are being post-translationally modified during
the process of IPA. Further work will be required to identify the modifications and the pro-
cesses involved. Additionally, we observe that IPA is associated with reduced levels of circulat-
ing RBP and APOA2 peptides, suggesting that these factors may be locally consumed during
tissue invasion or degradation of extracellular matrix.
The transition from Aspergillus colonization into invasive disease is a complex, orchestrated
response of the fungus interacting with the host. Stimulated by changes in the microenviron-
ment, inhaled conidia transform into hyphae, where fungal growth results in direct angio-inva-
sion releasing GM and BG into the circulation [6, 7]. Previous work has identified elevated
endothelial products including vWF and Factor VIII in of chronic necrotizing bronchopul-
monary aspergillosis [24]. Although measured, these factors were not found to be elevated in
this cohort. Taken together with our finding that biomarker patterns are different in patients
with primary hematological malignancy (leukemia) vs lung transplants, and stem cell trans-
plants, informative host response biomarkers of IPA may be highly dependent on the primary
underlying disease state. Further quantitative proteomics analysis of probably cases of IPA in
lung transplants or stem cell transplants will be required to identify disease-relevant pathways
and markers of IPA in these conditions.
Produced as a consequence of hyphal growth, the polysaccharide GM is used clinically for
the identification of IPA [9, 11, 12] [30]. Because of its uptake by neutrophils, variations in
assay performance by site of infection, previous anti-fungal therapy, or antigen clearance, GM
measurement is unreliable as a stand-alone diagnostic of IPA [11]. In this study, although the
mean population measurements of GM is increased in cases vs controls, a GPS classifier based
on GM alone is unstable and unlikely to generalize. Similarly, BG is a cell wall component pres-
ent in Aspergillus and a wide variety of other pathogenic fungi including Candida, Fusarium,
and Pneumocystis. As a diagnostic for IPA, BG measurements may be artifactually influenced
by Candida colonization, or bacterial infections [31]. We note that BG produces poor perfor-
mance classifiers in much the same manner as those by GM, and in combination, a classifier
built with both GM and BG does not produce a robust AUC for predicting independent test
data (not shown). By contrast, classification performance of a panel including these two fungal
antigens and host response markers provide greater diagnostic power for leukemic IPA than
either host response or fungal antigens alone.
Although the design of this experiment was not to identify pathogenic mechanisms in IPA,
the spectrum of 66 proteins that we identified may provide some insights into host response to
IPA in leukemic patients. Previous work has shown that the complement cascade represents a
crucial first line of innate defense against invasive fungi [32, 33]. Upon contact with plasma,
Aspergillus activates the classical-, lectin-, and alternative complement pathways that collec-
tively converge on the C3b convertase. Downstream of activated C3b, formation of the termi-
nal membrane attack complex results in pathogen killing [34–36]. We observe that
complement factors B, C3, and C4A are differentially expressed by IPA patients and are sub-
jected to post-translational modifications (Table 3). These data suggest that complement con-
sumption is a component of the pathogenesis of leukemic IPA.
Multiple fibrinogen (FIB) isoforms were also identified in our differential analysis, including
FIB-A and -B (Table 3). Other studies have shown that fibrinogen specifically binds to Aspergil-
lus fumigatus conidia in a dose-dependent manner, appearing to be involved in promoting cell
adhesion [37]. It is interesting to us that FIB levels are increased in IPA cases, suggesting their
enhanced synthesis in response to fungal dissemination. FIB is induced by IL-6, a cytokine
whose expression is enhanced in IPA by our ELISA measurements, perhaps suggesting that an
IL-6-FIB pathway is activated in response to angioinvasion in patients with leukemia. Leucine-
rich glycoprotein (LRG) is also differentially expressed and an informative component of our
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biomarker panel. LRG is also involved in cellular adhesion, although its role in promoting fun-
gal host invasion has not been elucidated to our knowledge.
Angio-invasion in IPA is partly dependent on the secretion of extracellular proteinases and
ribonucleotoxin [38]. We also note that AATC and alpha-1-acid glycoprotein antiproteases are
also differentially expressed. We surmise that induction and consumption of AATC and A1AG
are observed in high probability IPA.
Finally, there are several important limitations of this study. One limitation is the low num-
ber of subjects in the verification arm indicating that this study will need to be extended to a
larger cohort. A second limitation is that our 2DE analysis identified a number of post-transla-
tionally modified and proteolyzed peptides for which we could not selectively measure. More
advances in understanding the nature of these post-translational modifications and develop-
ment of methods to detect them in a complex background of plasma may improve the perfor-
mance of the host response proteins as a classifier. Our study design was not intended to assess
specificity of the panel for other invasive fungal diseases. Further work will be required to
determine the performance of these markers in patients with other types of invasive fungal
diseases.
Summary and potential applications
IPA is important opportunistic infection affecting immunocompromised patients. Guided by
the need to establish an early diagnosis, we have identified, confirmed, and evaluated a multi-
component predictive panel for the presence of IPA in a prospective cohort of immunocom-
promised patients in a multi-center registry. Two important findings are that host response
proteins contribute independent information to that of GM or BG, and that diagnostic host
response proteins of IPA are significantly influenced by the primary underlying disease. Our
findings may suggest strategies for further refining diagnostics to identify early stages of angio-
invasion in IPA arising during intensive chemotherapy for leukemia.
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